Compare Angi Inc (ANGI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Angi Inc vs Sana Biotechnology Inc — how do they compare? Angi Inc trades at $5.3 (market cap $214.95M), while Sana Biotechnology Inc trades at $3.1 (market cap $928.02M). The key difference: Sana Biotechnology Inc is far larger — about 4.3× Angi Inc's market cap, and Sana Biotechnology Inc is more actively traded (2,916,016 versus 1,375,952). Which is the better fit depends on your goals — on Pluang, investors hold Angi Inc for 42 Days and Sana Biotechnology Inc for 22 Days on average.
| ANGI | SANA | |
|---|---|---|
Market Cap | $214.95M | $928.02M |
Volume | 1,375,952 | 2,916,016 |
Sector | Media | Health |
52-Week High | $18.08 | $5.92 |
52-Week Low | $4.33 | $2.68 |
Typical Hold Time | 42 Days | 22 Days |
Enterprise Value | $424.72M | $841.27M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ANGI trades at $5.30, showing minimal daily movement with a 0.19% gain. The stock exhibits mixed technical signals with a bullish overall trend but neutral oscillators. Fundamentally, the company faces challenges with declining revenue from $1.9B in 2022 to $993M projected for 2026, though valuation ratios appear attractive with P/E of 14.81 and P/S of 0.22. Recent developments include AI integration partnerships with ChatGPT and Gemini, positioning the company for technological advancement.
The investment outlook presents both opportunity and risk. Attractive valuation metrics and AI partnerships offer potential upside, but declining revenue, negative profit margins (-22.35% net income margin), and inconsistent earnings performance create significant headwinds. Analyst consensus leans cautious with 63.63% hold ratings, though the $8.75 price target suggests 65% upside potential from current levels.
SANA Biotechnology trades at $3.10, up 6.16% today, but faces significant fundamental challenges with negative profitability metrics including -152.87% ROE and -$244.17M net loss for 2025. The company maintains strong analyst support with 82% buy ratings despite recent earnings misses and negative cash flow. Technical indicators show bearish momentum with the stock trading at key support levels around $3.00.
While analyst consensus remains optimistic with a $9.50 price target, investors face substantial risks from ongoing cash burn, negative earnings trajectory, and potential fiduciary concerns highlighted in recent news. The stock's outlook depends heavily on clinical trial progress and future funding requirements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Angi Inc
Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. It has two geographical segments namely North America (the United States and Canada), which primarily includes the operations HomeAdvisor, Angie's List, Handy, mHelpDesk, HomeStars, and Fixd Repair
Read more on ANGI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
